Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:HROW NASDAQ:LXEO NASDAQ:MLTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$5.23-5.8%$6.07$3.74▼$8.40$1.37B0.584.10 million shs8.98 million shsHROWHarrow$41.15-2.2%$37.06$28.54▼$54.85$1.57B0.28803,602 shs482,986 shsLXEOLexeo Therapeutics$4.81+1.3%$5.21$3.60▼$10.99$372.98M1.39914,864 shs1.04 million shsMLTXMoonLake Immunotherapeutics$19.91+0.1%$18.21$5.95▼$62.75$1.46B1.041.23 million shs1.31 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx0.00%-8.51%-8.36%-0.27%+50.00%HROWHarrow0.00%-1.87%+19.48%+26.34%+36.24%LXEOLexeo Therapeutics0.00%-3.65%-7.59%-9.87%+15.29%MLTXMoonLake Immunotherapeutics0.00%+3.59%+3.75%+17.54%-58.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$5.23-5.8%$6.07$3.74▼$8.40$1.37B0.584.10 million shs8.98 million shsHROWHarrow$41.15-2.2%$37.06$28.54▼$54.85$1.57B0.28803,602 shs482,986 shsLXEOLexeo Therapeutics$4.81+1.3%$5.21$3.60▼$10.99$372.98M1.39914,864 shs1.04 million shsMLTXMoonLake Immunotherapeutics$19.91+0.1%$18.21$5.95▼$62.75$1.46B1.041.23 million shs1.31 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx0.00%-8.51%-8.36%-0.27%+50.00%HROWHarrow0.00%-1.87%+19.48%+26.34%+36.24%LXEOLexeo Therapeutics0.00%-3.65%-7.59%-9.87%+15.29%MLTXMoonLake Immunotherapeutics0.00%+3.59%+3.75%+17.54%-58.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 2.91Moderate Buy$15.73200.71% UpsideHROWHarrow 2.64Moderate Buy$69.4368.72% UpsideLXEOLexeo Therapeutics 2.89Moderate Buy$18.75289.81% UpsideMLTXMoonLake Immunotherapeutics 2.38Hold$23.8519.77% UpsideCurrent Analyst Ratings BreakdownLatest LXEO, MLTX, HROW, and ARDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/25/2026LXEOLexeo Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$12.00 ➝ $9.006/16/2026ARDXArdelyx LADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$16.006/11/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/9/2026MLTXMoonLake Immunotherapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.006/8/2026MLTXMoonLake Immunotherapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.005/29/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026LXEOLexeo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/13/2026HROWHarrow Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$91.00 ➝ $88.005/12/2026MLTXMoonLake Immunotherapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/12/2026HROWHarrow BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$63.00(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$407.32M3.17N/AN/A$0.69 per share7.58HROWHarrow$272.30M5.63$0.85 per share48.68$1.41 per share29.18LXEOLexeo TherapeuticsN/AN/AN/AN/A$3.38 per shareN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$4.27 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$61.60M-$0.23N/A9.34N/A-13.58%-38.11%-11.85%8/3/2026 (Estimated)HROWHarrow-$5.14M-$0.41N/A19.05N/A-5.57%19.59%2.26%8/10/2026 (Estimated)LXEOLexeo Therapeutics-$99.96M-$1.45N/AN/AN/AN/A-47.48%-41.72%8/13/2026 (Estimated)MLTXMoonLake Immunotherapeutics-$227.32M-$3.87N/AN/AN/AN/A-85.15%-60.52%8/4/2026 (Estimated)Latest LXEO, MLTX, HROW, and ARDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026HROWHarrow-$0.43-$0.74-$0.31-$0.74$52.43 million$44.20 million5/11/2026Q1 2026LXEOLexeo Therapeutics-$0.29-$0.25+$0.04-$0.25N/AN/A5/11/2026Q1 2026MLTXMoonLake Immunotherapeutics-$0.91-$0.98-$0.07-$0.98N/AN/A4/30/2026Q1 2026ARDXArdelyx-$0.13-$0.15-$0.02-$0.15$92.78 million$94.47 million3/30/2026Q4 2025LXEOLexeo Therapeutics-$0.32-$0.27+$0.05-$0.27N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/AHROWHarrowN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.373.493.28HROWHarrow10.302.482.30LXEOLexeo TherapeuticsN/A14.1614.16MLTXMoonLake Immunotherapeutics0.398.608.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%HROWHarrow72.76%LXEOLexeo Therapeutics60.67%MLTXMoonLake Immunotherapeutics93.85%Insider OwnershipCompanyInsider OwnershipARDXArdelyx5.30%HROWHarrow12.80%LXEOLexeo Therapeutics2.00%MLTXMoonLake Immunotherapeutics12.05%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90247.03 million233.94 millionOptionableHROWHarrow18037.28 million32.50 millionOptionableLXEOLexeo Therapeutics5878.52 million76.95 millionNot OptionableMLTXMoonLake Immunotherapeutics273.61 million64.74 millionOptionableLXEO, MLTX, HROW, and ARDX HeadlinesRecent News About These CompaniesMoonLake Immunotherapeutics - Ordinary Shares - Class AJune 26 at 6:08 PM | money.usnews.comMoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label ExpansionJune 26 at 4:02 PM | seekingalpha.comHow Investors May Respond To MoonLake Immunotherapeutics (MLTX) VELA Data And Upsized Follow-On OfferingJune 25, 2026 | finance.yahoo.comMoonLake Immunotherapeutics Announces $200 Million Public OfferingJune 25, 2026 | tipranks.comGuggenheim Remains a Buy on MoonLake Immunotherapeutics (MLTX)June 24, 2026 | theglobeandmail.comWhy MoonLake Immunotherapeutics Stock Wilted on WednesdayJune 24, 2026 | fool.comWhy MoonLake Immunotherapeutics Stock Wilted on WednesdayJune 24, 2026 | fool.comMLTX stock extends pullback after biggest rally in over 6 months following skin disease trial data — a look at the latest developmentJune 24, 2026 | msn.comCaitong International Asset Management Co. Ltd Cuts Holdings in MoonLake Immunotherapeutics $MLTXJune 24, 2026 | marketbeat.comMoonLake Immunotherapeutics Prices $200 Million Public Offering of Class A Ordinary Shares and Pre-Funded WarrantsJune 23, 2026 | quiverquant.comQMoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public OfferingJune 23, 2026 | finance.yahoo.comMoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public OfferingJune 23, 2026 | globenewswire.comMoonLake Immunotherapeutics: Label Upside Drives The Next Leg HigherJune 23, 2026 | seekingalpha.comMLTX stock clocks best day in over 6 months — what’s driving the investor optimism?June 23, 2026 | msn.comMoonLake Immunotherapeutics Announces Proposed Public OfferingJune 22, 2026 | globenewswire.comWhy Is MoonLake Immunotherapeutics Stock Soaring Monday?June 22, 2026 | benzinga.comMoonLake Highlights Strong Phase 3 Sonelokimab HS ResultsJune 22, 2026 | tipranks.comMoonLake eyes FDA filing this fall on one-year results for skin treatmentJune 21, 2026 | seekingalpha.comWhy is MLTX stock rallying nearly 20% overnight?June 21, 2026 | msn.comMoonLake Immunotherapeutics Reports Week 52 Phase 3 VELA Results Showing Durable Sonelokimab Efficacy in Hidradenitis SuppurativaJune 21, 2026 | quiverquant.comQMoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026June 21, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLXEO, MLTX, HROW, and ARDX Company DescriptionsArdelyx NASDAQ:ARDX$5.23 -0.32 (-5.77%) Closing price 04:00 PM EasternExtended Trading$5.24 +0.01 (+0.29%) As of 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Harrow NASDAQ:HROW$41.15 -0.92 (-2.19%) Closing price 04:00 PM EasternExtended Trading$41.86 +0.70 (+1.71%) As of 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.Lexeo Therapeutics NASDAQ:LXEO$4.81 +0.06 (+1.26%) Closing price 04:00 PM EasternExtended Trading$4.81 0.00 (0.00%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.MoonLake Immunotherapeutics NASDAQ:MLTX$19.91 +0.01 (+0.05%) Closing price 04:00 PM EasternExtended Trading$19.90 -0.01 (-0.05%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right 5 Places Investors Can Hide If the AI Trade Keeps Cracking MarketBeat Week in Review – 06/22 - 06/26 Qualcomm’s Investor Day Just Changed the Growth Story Forever Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
